NEJM August 2026 Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica

This Week In Medicine · Aug 14, 2026 · 1m

This study investigates the efficacy of secukinumab, a monoclonal antibody, as a novel treatment for patients suffering from relapsed polymyalgia rheumatica. Because traditional steroid therapies often lead to dangerous side effects and frequent relapses, researchers tested whether blocking the interleukin-17A protein could provide a safer, more stable alternative. The results demonstrated that patients receiving the drug were significantly more likely to achieve sustained remission while requiring a lower cumulative dose of glucocorticoidscompared to those on a placebo. Ultimately, the trial…